How did we arrive at neurological cell therapy solutions? Dr. Ole Isacson explores the stem cell steppingstones – from blood transfusions to Parkinson’s Disease treatments.

Which steps are needed to hire the best and brightest at CROs? Get a better understanding of the challenges facing today’s recruiters and explore these seven tips for hiring and retaining top CRO talent.

Is the clinical trial setting the best environment to ensure a patient’s safety? Dr. Jamie P. Dwyer discusses how nephrology clinical trials identify future patient risk factors for medication and treatment in the real-world setting.

What if you held a clinical trial and no one showed up? With clinical trial delays reaching up to $8M per day, discover why trial stakeholders need to be acutely aware of their study in order to make it a success.

Why doesn’t a cure exist yet for Alzheimer's disease? There is no simple answer to this question. However, a deeper understanding of the disease process and a closer look at clinical trial challenges may help to shed some light.

Dr. Robert Negrin explains the need to embrace both serendipity and complexity in order to better understand precision medicine.

Chronic kidney disease has become inextricably linked with cardiovascular conditions, a discovery that has yielded synergistic diagnosis and intervention methods. Dr. Jamie Dwyer explores the connection between these two diseases, which has brought about a sort of renaissance for nephrology research.

One of the tenets of clinical research is that findings often result in more questions than answers. For Huntington’s disease, the journey toward understanding and treatment continues to be a methodical one. Dr. Ole Isacson highlights two pathways to ongoing research for this rare disease.

While there are socioeconomic factors contributing to the reasons behind the lack of diversity, the exclusion of minority populations in clinical trials can be a scientifically flawed misstep. By focusing on a single demographic, clinical research findings become limited, and by ignoring other representative populations, "unexpected" side effects may be more commonplace while treatment success levels will vary.

Cell therapy has moved beyond “science fiction” and into effective FDA-approved treatment for three key hematological cancers. Hematologist Dr. Robert S. Negrin takes a deeper dive into identifying and understanding the central differentiators in cell therapy clinical trials.

Alzheimer’s Disease currently afflicts close to 50 million people worldwide, highlighting the importance of clinical trials for this condition. Alzheimer’s studies are unique in that they require an additional participant to assess the patient’s mental and physical health during the trial. But what are the characteristics of a viable study partner?

Oncology trials may start out similarly to other therapeutic indications, but they differ radically in relation to early phases of the study, biomarkers, drug characteristics, and competition for patients.  In this article, Dr. Alex Adjei speaks about the top four differentiators in oncology studies that make them unique among other trials.

Diagnostics and treatment for Alzheimer’s Disease vary – both around the world and around the block. In this article, read how recognizing the common disparities for these clinical trials, ranging from standards of care to lack of diversity, brings sponsors and other stakeholders closer to maintaining standardized protocols for Alzheimer’s studies.

Clinical sites that have a great deal of experience are generally sought after, but can often be busy running other trials. It may be beneficial to consider less experienced sites in order to have more trial options. But of course, there are some necessary considerations when turning to these sites.